Carboplatin

Evidence Level: L5

Predicted Indications: 9

Carboplatin

Pharmacist Assessment Report

Carboplatin: platinum-based DNA-crosslinking cytotoxic agent → rectum mucinous adenocarcinoma

One-Sentence Summary

Carboplatin is a platinum-based cytotoxic chemotherapy agent. The TxGNN model predicts it may be effective for rectum mucinous adenocarcinoma, but the data compiled for this report contain no clinical trials and no publications for this disease, so the prediction rests on the model alone.

Quick Overview

Item	Content
Original Indication	Not recorded in the local data
Predicted New Indication	rectum mucinous adenocarcinoma
TxGNN Prediction Score	0.9928
Evidence Level	L5
Australia Market Status	Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data
Number of PBS Items	1 (valid: 1)
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism of action data are not available in the data compiled for this report. Carboplatin belongs to the platinum class of cytotoxic drugs, which act by forming DNA crosslinks in dividing tumour cells.

The prediction likely reflects a shared mucinous adenocarcinoma phenotype with ovarian mucinous tumours, rather than any direct evidence in rectal cancer. Platinum agents are also reported to have limited efficacy in mucinous colorectal histology, which weakens the mechanistic argument. The score is a computational output only and should not be read as clinical support.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

Australia Market Information

ARTG Number	Product Name	Dosage Form	Approved Indication
ARTG 4309T	Carboplatin Accord	Solution for I.V. injection 450 mg in 45 mL	Not recorded in the local data

One licence is recorded, and it is valid. Carboplatin is supplied as an injectable (intravenous) solution.

Cytotoxicity

Item	Content
Cytotoxicity Classification	Conventional cytotoxic (platinum class)
Myelosuppression Risk	High (thrombocytopenia, neutropenia, leukopenia and anaemia are recognised concerns)
Emetogenicity Classification	Please refer to the Product Information (PI) warnings and precautions
Monitoring Items	Full blood count with differential, liver and renal function; also consider hearing and peripheral neurological assessment
Handling Protection	Must follow cytotoxic drug handling regulations

Safety Considerations

No label-based warnings or contraindications are available in the data compiled for this report. Please refer to the TGA-approved Product Information (PI) for safety information.

Conditions listed as contraindication-related in the compiled data (these are not label text):

Kidney disease, liver disease, gallbladder disease
Thrombocytopenia, neutropenia, agranulocytosis, leukopenia, anaemia (including macrocytic anaemia), blood coagulation disease
Peripheral neuropathy and peripheral nervous system disease
Hearing and auditory system disorders
Functional visual loss

Drug interactions: 100 interactions were identified. The main ones listed are mostly of moderate severity:

Proton pump inhibitors: rabeprazole, omeprazole, esomeprazole, lansoprazole, dexlansoprazole, pantoprazole
Aminoglycosides and glycopeptides: kanamycin, neomycin, streptomycin, vancomycin
Statins: rosuvastatin, simvastatin
Nitroimidazoles: metronidazole, tinidazole
Minor: levofloxacin

Conclusion and Next Steps

Decision: Hold

Rationale: The prediction score is high (0.9928), but there are no clinical trials or publications for rectum mucinous adenocarcinoma, so the evidence level is L5. Platinum agents are also reported to have limited efficacy in mucinous colorectal histology.

To proceed, the following is needed:

Any direct clinical or preclinical evidence of carboplatin activity in rectal mucinous adenocarcinoma
Mechanism of action data to support the proposed link
Label-based warnings and contraindications from the TGA-approved Product Information
A review of current rectal cancer guidelines to judge whether a platinum agent has a role in this histology
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.